Primary source: Download medicine data | European Medicines Agency (EMA)
The ASR module in the CTIS becomes mandatory for submitting Annual Safety Reports for clinical trials, requiring compliance with new submission protocols established under Regulation (EU) No 536/2014.
This change impacts clinical trial sponsors as they are required to adapt their safety reporting workflows to ensure compliance with the new mandatory channel for ASR submissions.
Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Introduction of a dedicated ASR safety module in CTIS; transition to a mandatory submission channel for ASRs; updated functionalities for managing safety reporting in the system; new process for accessing the CTIS training environment.
Clinical trial sponsors must prepare for the mandatory transition to the CTIS ASR module for safety report submissions. PV operations and clinical safety teams will need to update internal SOPs, train staff on the new module's functionalities, and use the CTIS training environment to ensure compliance with the new submission workflow.
Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.
The new ASR module will be the required method for submitting and managing Annual Safety Reports, analogous to Development Safety Update Reports (DSURs). This transition necessitates that clinical trial sponsors prepare by updating internal procedures and training staff on the new system functionalities.
What changed: The ASR module in the CTIS becomes mandatory for submitting Annual Safety Reports for clinical trials, requiring compliance with new submission protocols established under Regulation (EU) No 536/2014.
Why it matters: This change impacts clinical trial sponsors as they are required to adapt their safety reporting workflows to ensure compliance with the new mandatory channel for ASR submissions.
Practical implication: Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
